29 completed, 6 terminated, 3 unknown, 1 recruiting. 40 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 40 | Completed 29, Terminated 6, Unknown 3, Recruiting 1, Withdrawn 1 |
| Phase 2 | 12 | Completed 6, Terminated 3, Unknown 2, Withdrawn 1 |
Follow nilotinib: new trials by email Literature Review of nilotinib trials Research Report on nilotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions. XS003 (nilotinib), Tasigna (nilotinib) - Cancer | Phase 1 | Completed | Xspray Pharma AB | 128 | 2024-11-15 | 2025-08-22 |
| Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg - Metastatic Melanoma, BRAF Gene Mutation | Phase 1 | Recruiting | Rina Plattner | 30 | 2022-06-01 | 2026-02-13 |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia KRT-232, Dasatinib, Nilotinib - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 109 | 2021-05-07 | 2022-03-21 |
| Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Nilotinib, Nilotinib Hydrochloride Monohydrate, Paclitaxel - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 11 | 2020-12-11 | 2025-06-29 |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Eicosapentaenoic Acid, Tyrosine kinase inhibitor - Chronic Myeloid Leukemia, Chronic Phase | Phase 1 / Phase 2 | Terminated | Milton S. Hershey Medical Center | 1 | 2020-09-14 | 2022-07-01 |
| A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin Metformin, Metformin + Nilotinib - Healthy | Phase 1 | Completed | Hyewon Chung | 16 | 2020-07-23 | 2020-11-04 |
| Nilotinib in Huntington's Disease Nilotinib 150 MG - Huntington Disease | Phase 1 | Unknown | Georgetown University | 10 | 2018-11-15 | 2020-02-20 |
| A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Nilotinib, Ruxolitinib - Leukemia, Chronic Myeloid | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2018-01-01 | 2021-02-16 | |
| Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors Nilotinib + Paclitaxel - Solid Tumors | Phase 1 | Completed | National Cancer Institute (NCI) | 47 | 2015-04-13 | 2026-09-28 |
| An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) MEK-162, Nilotinib, Questionnaires - Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2015-03-11 | 2020-02-12 |
| Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients Nilotinib, Ruxolitinib - Chronic Myeloid Leukemia | Phase 1 | Completed | Novartis Pharmaceuticals | 5 | 2015-02-18 | 2019-05-01 |
| Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 Nilotinib - Parkinson's Disease, Parkinson's Disease Dementia | Phase 1 | Completed | Georgetown University | 12 | 2014-11-01 | 2015-12-16 |
| A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors Nilotinib + Cetuximab - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Terminated | Georgetown University | 15 | 2014-05-01 | 2019-02-08 |
| A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Asciminib (ABL001), Nilotinib, Imatinib - Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Phase 1 | Completed | Novartis Pharmaceuticals | 326 | 2014-04-24 | 2024-03-18 |
| Pharmacokinetic Comparison of XS003 and Tasigna XS003, Tasigna - Healthy | Phase 1 | Completed | XSpray Microparticles | 27 | 2013-12-01 | 2014-11-11 |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 4 | 2013-08-01 | 2020-11-02 |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors Dasatinib, Imatinib Mesylate, Nilotinib - Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission | Phase 1 | Terminated | M.D. Anderson Cancer Center | 8 | 2013-07-24 | 2025-06-03 |
| Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults Nilotinib, Vinblastine - Refractory Low-grade Gliomas, Recurrent Low-grade Gliomas | Phase 1 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 35 | 2013-05-29 | 2022-05-27 |
| Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Nilotinib, Ruxolitinib - Chronic Phase Chronic Myeloid Leukemia | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 11 | 2013-02-21 | 2021-01-05 |
| Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Nilotinib, interferon-alfa - Chronic Myeloid Leukemia | Phase 1 | Completed | Novartis Pharmaceuticals | 4 | 2012-04-01 | 2015-05-05 |
Showing 20 of 40. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Myeloid, Chronic-Phase (5) · Blast Crisis (3) · Neoplasms (3) · Gastrointestinal Stromal Tumors (2) · Leukemia (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Acute (2) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Squamous Cell (1) · Chondrosarcoma (1) · Chordoma (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1)
Novartis Pharmaceuticals (14) · Georgetown University (3) · M.D. Anderson Cancer Center (2) · University Health Network, Toronto (2) · Broto, Javier MartÃn, M.D. (1) · Fred Hutchinson Cancer Center (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hyewon Chung (1) · Jan Beumer (1) · Kartos Therapeutics, Inc. (1) · Massachusetts General Hospital (1) · Milton S. Hershey Medical Center (1) · National Cancer Institute (NCI) (1)
United States (21) · Italy (9) · France (8) · Germany (8) · Canada (6) · Spain (6) · United Kingdom (5) · Netherlands (4) · South Korea (4) · Japan (3) · Australia (2) · Austria (2) · Denmark (2) · Poland (2) · Singapore (2)
Alice P Chen, M.D. (1) · Andreas Hochhaus, Prof. Dr. med. (1) · Ann W Gramza, MD (1) · Attilio Olivieri, MD (1) · David Miklos (1) · Dennis Kim, MD/PhD (1) · Edwin Choy, MD, PhD (1) · George Chen (1) · Hagop M. Kantarjian, MD (1) · Hyewon Chung, MD, PhD (1) · Jan H. Beumer, PharmD, PhD (1)
PMID 16775235, PMID 17715389, PMID 18048643, PMID 20110053, PMID 21098399, PMID 23065514, PMID 23547655, PMID 24057647, PMID 26002753, PMID 27434297, PMID 29051021, PMID 30340199, PMID 31826340, PMID 32666050, PMID 33142018, PMID 35764773, PMID 38755421, PMID 39374521, PMID 40680102
2005 (1), 2009 (1), P01CA018029 (1), P30CA015704 (1), P30CA016672 (1), R01CA238946 (1), R01CA258751 (1)